The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Economic burden of Alzheimer disease and managed care considerations
Open accessAbstract
Alzheimer disease is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. The estimated total healthcare costs for the treatment of Alzheimer disease in 2020 is estimated at $305 billion, with the cost expected to increase to more than $1 trillion as the population ages. Most of the direct costs of care for Alzheimer disease are attributed to skilled nursing care, home healthcare, and hospice care. Indirect costs of care, including quality of life and informal caregiving, are likely underestimated and are associated with significant negative societal and personal burden. Managed care organizations are in a unique position to develop utilization strategies that would positively impact early diagnosis and treatment to lead to better outcomes and lower costs for patients, caregivers, and the healthcare system. Additionally, the recent inclusion of Alzheimer disease diagnoses into risk corridor calculations by the Centers for Medicare & Medicaid Services may encourage Medicare Advantage organizations to invest in programs that aid in its early detection and diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659
Mokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Matthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3063 · Cited by 1,124
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Petersen, R. C. (2016) · Continuum · doi:10.1212/con.0000000000000313 · Cited by 909
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
DeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 670
Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0677 · Cited by 637
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603
Cordell, C. B., Borson, S., Boustani, M., Chodosh, J., Reuben, D., Verghese, J., Thies, W., Fried, L. B., & Workgroup, M. D. O. C. I. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.011 · Cited by 578
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564
Wang, H., Li, T., Barbarino, P., Gauthier, S., Brodaty, H., Molinuevo, J. L., Xie, H., Sun, Y., Yu, E., Tang, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30755-8 · Cited by 562
Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
Dubois, B., Padovani, A., Scheltens, P., Rossi, A., & Dell’Agnello, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150692 · Cited by 562
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Anticholinergic drugs and risk of dementia: case-control study
Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Grossi, C. M., Mattishent, K., Bennett, K., et al. (2018) · BMJ · doi:10.1136/bmj.k1315 · Cited by 520
Evidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507
Alzheimer’s Disease – Why We Need Early Diagnosis
Rasmussen, J., & Langerman, H. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s228939 · Cited by 501
Brown, E. E., Kumar, S., Rajji, T. K., Pollock, B. G., & Mulsant, B. H. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.04.010 · Cited by 483
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473
Fleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448
Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000354370 · Cited by 426
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Brookmeyer, R., Abdalla, N., Kawas, C. H., & Corrada, M. M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.009 · Cited by 406
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.0435 · Cited by 374
The Burden of Health Care Costs for Patients With Dementia in the Last 5 Years of Life
Kelley, A. S., McGarry, K., Gorges, R., & Skinner, J. S. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0381 · Cited by 373
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
Sperling, R. A., Donohue, M. C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K., Siemers, E., Johnson, K. A., Aisen, P. S., & for the A4 Study Team (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0387 · Cited by 324
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
A resurrection of aducanumab for Alzheimer's disease
Schneider, L. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30480-6 · Cited by 286
The impact of early dementia diagnosis and intervention on informal caregivers
de Vugt, M. E., & Verhey, F. R. J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.005 · Cited by 277
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes
Weimer, D. L., & Sager, M. A. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.01.028 · Cited by 257
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J., Feldman, H. H., & Scheltens, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 238
A Prescribing Cascade Involving Cholinesterase Inhibitors and Anticholinergic Drugs
Gill, S. S., Mamdani, M., Naglie, G., Streiner, D. L., Bronskill, S. E., Kopp, A., Shulman, K. I., Lee, P. E., & Rochon, P. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.7.808 · Cited by 234
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190426 · Cited by 216
Wessels, A. M., Tariot, P. N., Zimmer, J. A., Selzler, K. J., Bragg, S. M., Andersen, S. W., Landry, J., Krull, J. H., Downing, A. M., Willis, B. A., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3988 · Cited by 209
Early Detection of Mild Cognitive Impairment (MCI) in Primary Care
Sabbagh, M. N., Boada, M., Borson, S., Chilukuri, M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., et al. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.21 · Cited by 208
Practical Guidelines for the Recognition and Diagnosis of Dementia
Galvin, J. E., & Sadowsky, C. H. (2012) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2012.03.100181 · Cited by 201
Spector, A., Orrell, M., & Woods, B. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2464 · Cited by 196
Howard, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States
Deb, A., Thornton, J. D., Sambamoorthi, U., & Innes, K. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1313118 · Cited by 190
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline
Ryan, J., Storey, E., Murray, A. M., Woods, R. L., Wolfe, R., Reid, C. M., Nelson, M. R., Chong, T. T. J., Williamson, J. D., Ward, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009277 · Cited by 182
Brookmeyer, R., & Abdalla, N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.005 · Cited by 176
Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., Thompson, Y., Tricco, A. C., & Straus, S. E. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0993 · Cited by 159
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R. R., Riviere, M., Caputo, A., Sóvágó, J., Maguire, R. P., Farlow, M. R., Marotta, G., Sánchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 157
Medication Adherence in Older Patients With Dementia: A Systematic Literature Review
El‐Saifi, N., Moyle, W., Jones, C., & Tuffaha, H. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017710524 · Cited by 142
Zhu, C. W., Scarmeas, N., Ornstein, K., Albert, M., Brandt, J., Blacker, D., Sano, M., & Stern, Y. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.018 · Cited by 137
Lin, P., Zhong, Y., Fillit, H. M., Chen, E., & Neumann, P. J. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14227 · Cited by 127
First do no harm: a real need to deprescribe in older patients
Scott, I. A., Anderson, K., Freeman, C. R., & Stowasser, D. A. (2014) · The Medical Journal of Australia · doi:10.5694/mja14.00146 · Cited by 123
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 122
Rockwood, K. J., Fay, S., Gorman, M., Carver, D., & Graham, J. (2007) · BMC Neurology · doi:10.1186/1471-2377-7-26 · Cited by 116
Boada, M., López, O., Núñez, L., Szczepiorkowski, Z. M., Torres, M., Grifols, C., & Páez, A. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.01.001 · Cited by 91
Fink, H. A., Linskens, E. J., MacDonald, R. H., Silverman, P. C., McCarten, J. R., Talley, K. M., Forte, M. L., Desai, P. J., Nelson, V. A., Miller, M. A., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3887 · Cited by 91
Hampel, H., Williams, C., Etcheto, A., Goodsaid, F., Parmentier, F., Sallantin, J., Kaufmann, W. E., Missling, C. U., & Afshar, M. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12013 · Cited by 84
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Amariglio, R. E., Buckley, R. F., Mormino, E. C., Marshall, G. A., Johnson, K. A., Rentz, D. M., & Sperling, R. A. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.08.005 · Cited by 80
Sabbagh, M. N., Hendrix, S. B., & Harrison, J. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.004 · Cited by 80
Current and evolving treatment strategies for the Alzheimer disease continuum
Marasco, R. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 80
Progressive support for activities of daily living for persons living with dementia
Prizer, L. P., & Zimmerman, S. (2018) · The Gerontologist · doi:10.1093/geront/gnx103 · Cited by 78
Dementia severity and the longitudinal costs of informal care in the Cache County population
Rattinger, G. B., Schwartz, S., Mullins, C. D., Corcoran, C., Zuckerman, I. H., Sanders, C., Norton, M. C., Fauth, E. B., Leoutsakos, J. S., Lyketsos, C. G., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.004 · Cited by 71
Coe, N. B., Skira, M. M., & Larson, E. B. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15552 · Cited by 64
A Longitudinal Analysis of the Lifetime Cost of Dementia
Yang, Z., Zhang, K., Lin, P., Clevenger, C. K., & Atherly, A. J. (2011) · Health Services Research · doi:10.1111/j.1475-6773.2011.01365.x · Cited by 60
Hemmy, L. S., Linskens, E. J., Silverman, P. C., Miller, M. A., Talley, K. M., Taylor, B. C., Ouellette, J. M., Greer, N. L., Wilt, T. J., Butler, M. E., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3889 · Cited by 60
Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline
Asanad, S., Fantini, M., Sultan, W., Nassisi, M., Felix, C. M., Wu, J., Karanjia, R., Ross‐Cisneros, F. N., Sagare, A. P., Zloković, B. V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232785 · Cited by 56
Nguyen, T. A., Gilmartin‐Thomas, J., Tan, E. C. K., Ellett, L. M. K., Eshetie, T. C., Gillam, M., & Reeve, E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190162 · Cited by 55
Home Health and Informal Care Utilization and Costs Over Time in Alzheimer's Disease
Zhu, C. W., Torgan, R., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M. C., & Stern, Y. (2008) · Home Health Care Services Quarterly · doi:10.1300/j027v27n01_01 · Cited by 53
Quality improvement in neurology: Mild cognitive impairment quality measurement set
Foster, N. L., Bondi, M. W., Das, R. R., Foss, M., Hershey, L. A., Koh, S., Logan, R., Poole, C., Shega, J. W., Sood, A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008259 · Cited by 51
Medicare Expenditures Among Nursing Home Residents With Advanced Dementia
Goldfeld, K. S., Stevenson, D. G., Hamel, M. B., & Mitchell, S. L. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.478 · Cited by 48
Suehs, B. T., Shah, S., Davis, C. D., Alvir, J. M., Faison, W. E., Patel, N. C., van Amerongen, D., & Bobula, J. D. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12694 · Cited by 42
Dwibedi, N., Findley, P. A., Wiener R, C., Shen, C., & Sambamoorthi, U. (2018) · Medical Care · doi:10.1097/mlr.0000000000000869 · Cited by 39
Preclinical Alzheimer Disease—Early Diagnosis or Overdiagnosis?
Langa, K. M., & Burke, J. F. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2629 · Cited by 32
Mar, J., Soto‐Gordoa, M., Arrospide, A., Moreno, F., & Martínez‐Lage, P. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0079-9 · Cited by 31
The Real-World Medicare Costs of Alzheimer Disease: Considerations for Policy and Care
Pyenson, B. S., Sawhney, T. G., Steffens, C., Rotter, D., Peschin, S., Scott, J., & Jenkins, E. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.7.800 · Cited by 31
Niznik, J. D., Zhao, X., He, M., Aspinall, S. L., Hanlon, J. T., Hanson, L. C., Nace, D. A., Thorpe, J. M., & Thorpe, C. T. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16241 · Cited by 30
Amyloid pathology in the progression to mild cognitive impairment
Insel, P. S., Hansson, O., Mackin, R. S., Weiner, M. W., & Mattsson, N. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.018 · Cited by 29
Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00223 · Cited by 28
On the horizon—the value and promise of the global pipeline of Alzheimer's disease therapeutics
Cole, M., & Seabrook, G. R. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12009 · Cited by 26
Moga, D. C., Beech, B. F., Abner, E. L., Schmitt, F. A., Khouli, R. H. E., Martinez, A. I., Eckmann, L., Huffmyer, M. J., George, R., & Jicha, G. A. (2019) · Trials · doi:10.1186/s13063-019-3993-0 · Cited by 25
Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing
Niznik, J. D., Zhao, X., He, M., Aspinall, S. L., Hanlon, J. T., Nace, D. A., Thorpe, J. M., & Thorpe, C. T. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12054 · Cited by 19
Selkoe, D. J. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00985 · Cited by 15
Frölich, L., Atri, A., Ballard, C. G., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180595 · Cited by 15
Mild cognitive impairment and progression to dementia: New findings
Breitner, J. C. S. (2014) · Neurology · doi:10.1212/wnl.0000000000000158 · Cited by 11
Green, A. R., Segal, J. B., Boyd, C. M., Huang, J., & Roth, D. L. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00181-z · Cited by 11
Cited by
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis
Ceban, F., Ling, S., Lui, L. M. W., Lee, Y., Gill, H., Teopiz, K. M., Rodrigues, N. B., Subramaniapillai, M., Di Vincenzo, J. D., Cao, B., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.12.020 · Cited by 1,554
Alzheimer’s Disease: Epidemiology and Clinical Progression
Tahami Monfared, A. A., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00338-8 · Cited by 629
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
The Impact of Systemic Inflammation on Alzheimer’s Disease Pathology
Xie, J., Van Hoecke, L., & Vandenbroucke, R. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796867 · Cited by 324
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Metadata
- Venue
- The American Journal of Managed Care
- Published
- 2020-08-01
- Volume
- 26
- Issue
- Suppl 8
- Pages
- S177-S183
- ISSN
- 1088-0224 (ISSN-L)
- 1936-2692
- OpenAlex
- W3080312596
- Cited by
- 398
- References
- 98
- FWCI
- 35.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.